ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global DNA Damage Response Drugs Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-10A5993
Home | Market Reports | Health| Pharmacy
Global DNA Damage Response Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global DNA Damage Response Drugs Market Research Report 2025

Code: QYRE-Auto-10A5993
Report
July 2025
Pages:82
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AbbVie
Astrazeneca plc
Bayer
BeiGene Ltd
Clovis Oncology
Debiopharm
Eli Lilly and Company
GlaxoSmithKline PLC
Merck
NMS Group SpA
Onxeo
Pfizer Inc
Repare Therapeutics
Sierra Oncology
Zentalis Pharmaceuticals

DNA Damage Response Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

DNA Damage Response Drugs Market

DNA Damage Response Drugs Market

The global market for DNA Damage Response Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for DNA Damage Response Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA Damage Response Drugs.
The DNA Damage Response Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global DNA Damage Response Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the DNA Damage Response Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of DNA Damage Response Drugs Market Report

Report Metric Details
Report Name DNA Damage Response Drugs Market
CAGR 5%
Segment by Type
  • Lynparza
  • Talzenna
  • Zejula
  • Rubraca
Segment by Application
  • Ovarian Cancer
  • Breast Cancer
  • Pancreatic Cancer
  • Prostate Cancer
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AbbVie Inc, AstraZeneca, Bayer, BeiGene, Clovis Oncology, Debiopharm, Eli Lilly and Company, GlaxoSmithKline, Merck, NMS Group SpA, Onxeo, Pfizer, Repare Therapeutics, Sierra Oncology, Zentalis Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of DNA Damage Response Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the DNA Damage Response Drugs Market report?

Ans: The main players in the DNA Damage Response Drugs Market are AbbVie Inc, AstraZeneca, Bayer, BeiGene, Clovis Oncology, Debiopharm, Eli Lilly and Company, GlaxoSmithKline, Merck, NMS Group SpA, Onxeo, Pfizer, Repare Therapeutics, Sierra Oncology, Zentalis Pharmaceuticals

What are the Application segmentation covered in the DNA Damage Response Drugs Market report?

Ans: The Applications covered in the DNA Damage Response Drugs Market report are Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer

What are the Type segmentation covered in the DNA Damage Response Drugs Market report?

Ans: The Types covered in the DNA Damage Response Drugs Market report are Lynparza, Talzenna, Zejula, Rubraca

Recommended Reports

Oncology Therapeutics

Genetic & RNA Drugs

Diagnostics & Bioassay

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global DNA Damage Response Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Lynparza
1.2.3 Talzenna
1.2.4 Zejula
1.2.5 Rubraca
1.3 Market by Application
1.3.1 Global DNA Damage Response Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Pancreatic Cancer
1.3.5 Prostate Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global DNA Damage Response Drugs Market Perspective (2020-2031)
2.2 Global DNA Damage Response Drugs Growth Trends by Region
2.2.1 Global DNA Damage Response Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 DNA Damage Response Drugs Historic Market Size by Region (2020-2025)
2.2.3 DNA Damage Response Drugs Forecasted Market Size by Region (2026-2031)
2.3 DNA Damage Response Drugs Market Dynamics
2.3.1 DNA Damage Response Drugs Industry Trends
2.3.2 DNA Damage Response Drugs Market Drivers
2.3.3 DNA Damage Response Drugs Market Challenges
2.3.4 DNA Damage Response Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top DNA Damage Response Drugs Players by Revenue
3.1.1 Global Top DNA Damage Response Drugs Players by Revenue (2020-2025)
3.1.2 Global DNA Damage Response Drugs Revenue Market Share by Players (2020-2025)
3.2 Global DNA Damage Response Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by DNA Damage Response Drugs Revenue
3.4 Global DNA Damage Response Drugs Market Concentration Ratio
3.4.1 Global DNA Damage Response Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by DNA Damage Response Drugs Revenue in 2024
3.5 Global Key Players of DNA Damage Response Drugs Head office and Area Served
3.6 Global Key Players of DNA Damage Response Drugs, Product and Application
3.7 Global Key Players of DNA Damage Response Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 DNA Damage Response Drugs Breakdown Data by Type
4.1 Global DNA Damage Response Drugs Historic Market Size by Type (2020-2025)
4.2 Global DNA Damage Response Drugs Forecasted Market Size by Type (2026-2031)
5 DNA Damage Response Drugs Breakdown Data by Application
5.1 Global DNA Damage Response Drugs Historic Market Size by Application (2020-2025)
5.2 Global DNA Damage Response Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America DNA Damage Response Drugs Market Size (2020-2031)
6.2 North America DNA Damage Response Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America DNA Damage Response Drugs Market Size by Country (2020-2025)
6.4 North America DNA Damage Response Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe DNA Damage Response Drugs Market Size (2020-2031)
7.2 Europe DNA Damage Response Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe DNA Damage Response Drugs Market Size by Country (2020-2025)
7.4 Europe DNA Damage Response Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific DNA Damage Response Drugs Market Size (2020-2031)
8.2 Asia-Pacific DNA Damage Response Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific DNA Damage Response Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific DNA Damage Response Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America DNA Damage Response Drugs Market Size (2020-2031)
9.2 Latin America DNA Damage Response Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America DNA Damage Response Drugs Market Size by Country (2020-2025)
9.4 Latin America DNA Damage Response Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa DNA Damage Response Drugs Market Size (2020-2031)
10.2 Middle East & Africa DNA Damage Response Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa DNA Damage Response Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa DNA Damage Response Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie Inc
11.1.1 AbbVie Inc Company Details
11.1.2 AbbVie Inc Business Overview
11.1.3 AbbVie Inc DNA Damage Response Drugs Introduction
11.1.4 AbbVie Inc Revenue in DNA Damage Response Drugs Business (2020-2025)
11.1.5 AbbVie Inc Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca DNA Damage Response Drugs Introduction
11.2.4 AstraZeneca Revenue in DNA Damage Response Drugs Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer DNA Damage Response Drugs Introduction
11.3.4 Bayer Revenue in DNA Damage Response Drugs Business (2020-2025)
11.3.5 Bayer Recent Development
11.4 BeiGene
11.4.1 BeiGene Company Details
11.4.2 BeiGene Business Overview
11.4.3 BeiGene DNA Damage Response Drugs Introduction
11.4.4 BeiGene Revenue in DNA Damage Response Drugs Business (2020-2025)
11.4.5 BeiGene Recent Development
11.5 Clovis Oncology
11.5.1 Clovis Oncology Company Details
11.5.2 Clovis Oncology Business Overview
11.5.3 Clovis Oncology DNA Damage Response Drugs Introduction
11.5.4 Clovis Oncology Revenue in DNA Damage Response Drugs Business (2020-2025)
11.5.5 Clovis Oncology Recent Development
11.6 Debiopharm
11.6.1 Debiopharm Company Details
11.6.2 Debiopharm Business Overview
11.6.3 Debiopharm DNA Damage Response Drugs Introduction
11.6.4 Debiopharm Revenue in DNA Damage Response Drugs Business (2020-2025)
11.6.5 Debiopharm Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company DNA Damage Response Drugs Introduction
11.7.4 Eli Lilly and Company Revenue in DNA Damage Response Drugs Business (2020-2025)
11.7.5 Eli Lilly and Company Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Details
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline DNA Damage Response Drugs Introduction
11.8.4 GlaxoSmithKline Revenue in DNA Damage Response Drugs Business (2020-2025)
11.8.5 GlaxoSmithKline Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck DNA Damage Response Drugs Introduction
11.9.4 Merck Revenue in DNA Damage Response Drugs Business (2020-2025)
11.9.5 Merck Recent Development
11.10 NMS Group SpA
11.10.1 NMS Group SpA Company Details
11.10.2 NMS Group SpA Business Overview
11.10.3 NMS Group SpA DNA Damage Response Drugs Introduction
11.10.4 NMS Group SpA Revenue in DNA Damage Response Drugs Business (2020-2025)
11.10.5 NMS Group SpA Recent Development
11.11 Onxeo
11.11.1 Onxeo Company Details
11.11.2 Onxeo Business Overview
11.11.3 Onxeo DNA Damage Response Drugs Introduction
11.11.4 Onxeo Revenue in DNA Damage Response Drugs Business (2020-2025)
11.11.5 Onxeo Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer DNA Damage Response Drugs Introduction
11.12.4 Pfizer Revenue in DNA Damage Response Drugs Business (2020-2025)
11.12.5 Pfizer Recent Development
11.13 Repare Therapeutics
11.13.1 Repare Therapeutics Company Details
11.13.2 Repare Therapeutics Business Overview
11.13.3 Repare Therapeutics DNA Damage Response Drugs Introduction
11.13.4 Repare Therapeutics Revenue in DNA Damage Response Drugs Business (2020-2025)
11.13.5 Repare Therapeutics Recent Development
11.14 Sierra Oncology
11.14.1 Sierra Oncology Company Details
11.14.2 Sierra Oncology Business Overview
11.14.3 Sierra Oncology DNA Damage Response Drugs Introduction
11.14.4 Sierra Oncology Revenue in DNA Damage Response Drugs Business (2020-2025)
11.14.5 Sierra Oncology Recent Development
11.15 Zentalis Pharmaceuticals
11.15.1 Zentalis Pharmaceuticals Company Details
11.15.2 Zentalis Pharmaceuticals Business Overview
11.15.3 Zentalis Pharmaceuticals DNA Damage Response Drugs Introduction
11.15.4 Zentalis Pharmaceuticals Revenue in DNA Damage Response Drugs Business (2020-2025)
11.15.5 Zentalis Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
AbbVie
Astrazeneca plc
Bayer
BeiGene Ltd
Clovis Oncology
Debiopharm
Eli Lilly and Company
GlaxoSmithKline PLC
Merck
NMS Group SpA
Onxeo
Pfizer Inc
Repare Therapeutics
Sierra Oncology
Zentalis Pharmaceuticals
List of Tables
 Table 1. Global DNA Damage Response Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Lynparza
 Table 3. Key Players of Talzenna
 Table 4. Key Players of Zejula
 Table 5. Key Players of Rubraca
 Table 6. Global DNA Damage Response Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global DNA Damage Response Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global DNA Damage Response Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global DNA Damage Response Drugs Market Share by Region (2020-2025)
 Table 10. Global DNA Damage Response Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global DNA Damage Response Drugs Market Share by Region (2026-2031)
 Table 12. DNA Damage Response Drugs Market Trends
 Table 13. DNA Damage Response Drugs Market Drivers
 Table 14. DNA Damage Response Drugs Market Challenges
 Table 15. DNA Damage Response Drugs Market Restraints
 Table 16. Global DNA Damage Response Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global DNA Damage Response Drugs Market Share by Players (2020-2025)
 Table 18. Global Top DNA Damage Response Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Damage Response Drugs as of 2024)
 Table 19. Ranking of Global Top DNA Damage Response Drugs Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by DNA Damage Response Drugs Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of DNA Damage Response Drugs, Headquarters and Area Served
 Table 22. Global Key Players of DNA Damage Response Drugs, Product and Application
 Table 23. Global Key Players of DNA Damage Response Drugs, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global DNA Damage Response Drugs Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global DNA Damage Response Drugs Revenue Market Share by Type (2020-2025)
 Table 27. Global DNA Damage Response Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global DNA Damage Response Drugs Revenue Market Share by Type (2026-2031)
 Table 29. Global DNA Damage Response Drugs Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global DNA Damage Response Drugs Revenue Market Share by Application (2020-2025)
 Table 31. Global DNA Damage Response Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global DNA Damage Response Drugs Revenue Market Share by Application (2026-2031)
 Table 33. North America DNA Damage Response Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America DNA Damage Response Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America DNA Damage Response Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe DNA Damage Response Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe DNA Damage Response Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe DNA Damage Response Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific DNA Damage Response Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific DNA Damage Response Drugs Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific DNA Damage Response Drugs Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America DNA Damage Response Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America DNA Damage Response Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America DNA Damage Response Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa DNA Damage Response Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa DNA Damage Response Drugs Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa DNA Damage Response Drugs Market Size by Country (2026-2031) & (US$ Million)
 Table 48. AbbVie Inc Company Details
 Table 49. AbbVie Inc Business Overview
 Table 50. AbbVie Inc DNA Damage Response Drugs Product
 Table 51. AbbVie Inc Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 52. AbbVie Inc Recent Development
 Table 53. AstraZeneca Company Details
 Table 54. AstraZeneca Business Overview
 Table 55. AstraZeneca DNA Damage Response Drugs Product
 Table 56. AstraZeneca Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 57. AstraZeneca Recent Development
 Table 58. Bayer Company Details
 Table 59. Bayer Business Overview
 Table 60. Bayer DNA Damage Response Drugs Product
 Table 61. Bayer Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 62. Bayer Recent Development
 Table 63. BeiGene Company Details
 Table 64. BeiGene Business Overview
 Table 65. BeiGene DNA Damage Response Drugs Product
 Table 66. BeiGene Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 67. BeiGene Recent Development
 Table 68. Clovis Oncology Company Details
 Table 69. Clovis Oncology Business Overview
 Table 70. Clovis Oncology DNA Damage Response Drugs Product
 Table 71. Clovis Oncology Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 72. Clovis Oncology Recent Development
 Table 73. Debiopharm Company Details
 Table 74. Debiopharm Business Overview
 Table 75. Debiopharm DNA Damage Response Drugs Product
 Table 76. Debiopharm Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 77. Debiopharm Recent Development
 Table 78. Eli Lilly and Company Company Details
 Table 79. Eli Lilly and Company Business Overview
 Table 80. Eli Lilly and Company DNA Damage Response Drugs Product
 Table 81. Eli Lilly and Company Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 82. Eli Lilly and Company Recent Development
 Table 83. GlaxoSmithKline Company Details
 Table 84. GlaxoSmithKline Business Overview
 Table 85. GlaxoSmithKline DNA Damage Response Drugs Product
 Table 86. GlaxoSmithKline Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 87. GlaxoSmithKline Recent Development
 Table 88. Merck Company Details
 Table 89. Merck Business Overview
 Table 90. Merck DNA Damage Response Drugs Product
 Table 91. Merck Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 92. Merck Recent Development
 Table 93. NMS Group SpA Company Details
 Table 94. NMS Group SpA Business Overview
 Table 95. NMS Group SpA DNA Damage Response Drugs Product
 Table 96. NMS Group SpA Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 97. NMS Group SpA Recent Development
 Table 98. Onxeo Company Details
 Table 99. Onxeo Business Overview
 Table 100. Onxeo DNA Damage Response Drugs Product
 Table 101. Onxeo Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 102. Onxeo Recent Development
 Table 103. Pfizer Company Details
 Table 104. Pfizer Business Overview
 Table 105. Pfizer DNA Damage Response Drugs Product
 Table 106. Pfizer Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 107. Pfizer Recent Development
 Table 108. Repare Therapeutics Company Details
 Table 109. Repare Therapeutics Business Overview
 Table 110. Repare Therapeutics DNA Damage Response Drugs Product
 Table 111. Repare Therapeutics Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 112. Repare Therapeutics Recent Development
 Table 113. Sierra Oncology Company Details
 Table 114. Sierra Oncology Business Overview
 Table 115. Sierra Oncology DNA Damage Response Drugs Product
 Table 116. Sierra Oncology Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 117. Sierra Oncology Recent Development
 Table 118. Zentalis Pharmaceuticals Company Details
 Table 119. Zentalis Pharmaceuticals Business Overview
 Table 120. Zentalis Pharmaceuticals DNA Damage Response Drugs Product
 Table 121. Zentalis Pharmaceuticals Revenue in DNA Damage Response Drugs Business (2020-2025) & (US$ Million)
 Table 122. Zentalis Pharmaceuticals Recent Development
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. DNA Damage Response Drugs Picture
 Figure 2. Global DNA Damage Response Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global DNA Damage Response Drugs Market Share by Type: 2024 VS 2031
 Figure 4. Lynparza Features
 Figure 5. Talzenna Features
 Figure 6. Zejula Features
 Figure 7. Rubraca Features
 Figure 8. Global DNA Damage Response Drugs Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global DNA Damage Response Drugs Market Share by Application: 2024 VS 2031
 Figure 10. Ovarian Cancer Case Studies
 Figure 11. Breast Cancer Case Studies
 Figure 12. Pancreatic Cancer Case Studies
 Figure 13. Prostate Cancer Case Studies
 Figure 14. DNA Damage Response Drugs Report Years Considered
 Figure 15. Global DNA Damage Response Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global DNA Damage Response Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global DNA Damage Response Drugs Market Share by Region: 2024 VS 2031
 Figure 18. Global DNA Damage Response Drugs Market Share by Players in 2024
 Figure 19. Global Top DNA Damage Response Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in DNA Damage Response Drugs as of 2024)
 Figure 20. The Top 10 and 5 Players Market Share by DNA Damage Response Drugs Revenue in 2024
 Figure 21. North America DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America DNA Damage Response Drugs Market Share by Country (2020-2031)
 Figure 23. United States DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe DNA Damage Response Drugs Market Share by Country (2020-2031)
 Figure 27. Germany DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Nordic Countries DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific DNA Damage Response Drugs Market Share by Region (2020-2031)
 Figure 35. China DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America DNA Damage Response Drugs Market Share by Country (2020-2031)
 Figure 43. Mexico DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa DNA Damage Response Drugs Market Share by Country (2020-2031)
 Figure 47. Turkey DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE DNA Damage Response Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. AbbVie Inc Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 51. AstraZeneca Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 52. Bayer Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 53. BeiGene Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 54. Clovis Oncology Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 55. Debiopharm Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 56. Eli Lilly and Company Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 57. GlaxoSmithKline Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 58. Merck Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 59. NMS Group SpA Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 60. Onxeo Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 61. Pfizer Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 62. Repare Therapeutics Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 63. Sierra Oncology Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 64. Zentalis Pharmaceuticals Revenue Growth Rate in DNA Damage Response Drugs Business (2020-2025)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

DNA Sequencing In Drug Discovery Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Therapy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Genome Based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Gene Therapy Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
DNA Probe based Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Predictive Genetic Testing and Genomics Market Research Report 2025
Global Cellular and Gene Therapy Product Market Research Report 2025
High density Multiplexed Diagnostic Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PCR Molecular Diagnostics Market Research Report 2024
Scar Removal Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Small Molecule Nucleic Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmacogenomics Technology Theranostics Companion Diagnostics CDx Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Genetic Disease Diagnosis Market Research Report 2024
Global Plasmid DNA Production Market Research Report 2025
Cell and Gene Therapy Bioassay Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmacogenomics Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Autoimmune Diseases Treatment Market Research Report 2024
AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non invasive Prenatal Genetic Testing Market Research Report 2025
Global Nucleic Acid based Drugs Market Research Report 2024

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions